Compare · MMED vs WST
MMED vs WST
Side-by-side comparison of MiniMed Group Inc. (MMED) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMED and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 4.9x MMED ($4.73B).
- Over the past year, MMED is down 8.0% and WST is up 27.6% - WST leads by 35.6 points.
- MMED has been more active in the news (11 items in the past 4 weeks vs 6 for WST).
- WST has more recent analyst coverage (18 ratings vs 12 for MMED).
- Company
- MiniMed Group Inc.
- West Pharmaceutical Services Inc.
- Price
- $16.80+2.85%
- $328.35-7.74%
- Market cap
- $4.73B
- $23.19B
- 1M return
- +18.81%
- -3.45%
- 1Y return
- -8.00%
- +27.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 11
- 6
- Recent ratings
- 12
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MMED
- MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
- MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
- SEC Form 3 filed by new insider Endicott David J.
- SEC Form 3 filed by new insider Burman Linnea
- SVP, Gen. Counsel, Corp. Sec. Wills Courtney Nelson was granted 82,787 shares, increasing direct ownership by 150% to 138,146 units (SEC Form 4)
- VP, Chief Accounting Officer Gyurci John was granted 24,244 shares, increasing direct ownership by 154% to 39,941 units (SEC Form 4)
- SVP, Chief HR Officer Chandrasena Gillian was granted 44,188 shares, increasing direct ownership by 34% to 174,844 units (SEC Form 4)
- EVP, Chief Financial Officer Spooner Chad was granted 116,607 shares, increasing direct ownership by 43% to 386,008 units (SEC Form 4)
- Officer Dianaty Ali was granted 131,312 shares, increasing direct ownership by 68% to 323,170 units (SEC Form 4)
- Chief Executive Officer Dallara Que was granted 297,618 shares, increasing direct ownership by 48% to 916,099 units (SEC Form 4)
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target